Funding to support the Phase 1 clinical trial of ER-100 in optic neuropathies and further investigation of new candidates from the company’s Partial Epigenetic Reprogramming platform BOSTON, April 8, ...

Lead epigenetic restoration therapy enters the clinic for glaucoma and NAION, targeting a root cause of age-related vision loss BOSTON, June 9, 2026 — Life Biosciences, Inc. (“Life Bio”), a ...

Forge to provide cGMP manufacturing and development services for Life Biosciences’ novel adeno-associated virus (AAV) gene therapy platform for aging-related diseases, including in ophthalmic ...

Data replicate and expand upon the potential of ER-100 to improve retinal ganglion cell function and restore visual function in a nonhuman primate model of nonarteritic anterior ischemic optic ...

These data, along with additional ER-100 preclinical data from a nonhuman primate model of NAION demonstrating clear restoration of methylation patterns with functional enrichment of neuronal ...

BOSTON, January 28, 2026 – Life Biosciences, Inc., (“Life Bio”) a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, today announced ...

BOSTON, October 1, 2026 – Life Biosciences (“Life Bio”), a biotechnology company pioneering cellular rejuvenation medicines to reverse diseases of aging, today announced that the company will present ...

Administration of ER-100 was well-tolerated through Day 56 in three participants with glaucoma, supporting dose escalation in the ongoing trial BOSTON, October 8, 2026 – Life Biosciences (“Life Bio”), ...

BOSTON, January 27, 2025 – Life Biosciences (“Life Bio”), a biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging, today announced the ...

This policy is in addition to the Conflict of Interest Policy that applies to all directors, executives and employees and certain independent contractors of Life Biosciences LLC and its wholly- and ...

BOSTON, Jan. 15, 2019 — Life Biosciences has announced the closing of a Series B financing round of $50 million, according to Tristan Edwards, chief executive officer and co-founder. The Company ...

Data in a nonhuman primate model of Non-arteritic Anterior Ischemic Optic Neuropathy (NAION) demonstrates the ability to restore visual function after delivery of a novel gene therapy BOSTON, April 23 ...